New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)

Oct 28, 2026

Roche Diagnostics $RHHBY Collaboration, Promising REQORSA® Biomarker Research, and Expanding Gene Therapy Programs Put Genprex $GNPX in the Spotlight

AUSTIN, Texas - Oct. 28, 2026 - PRLog -- Genprex, Inc. (N A S D A Q: GNPX) $GNPX is bringing renewed attention to its gene therapy platform with a new announcement today involving its sponsored research collaboration with Meharry Medical College. The research, centered on TUSC2—the tumor-suppressor gene used in Genprex's investigational REQORSA® gene therapy—will be presented at the Gerontological Society of America (GSA) 2026 Annual Scientific Meeting in November.

For investors following emerging biotechnology companies, this latest development adds another dimension to Genprex's scientific story. The company continues to investigate approaches designed to restore important biological functions, with programs targeting cancer and diabetes. Its expanding research into TUSC2 biology may provide valuable scientific insights beyond the gene's established role in oncology, while its clinical and development programs remain the central focus of its therapeutic ambitions.

Although Genprex remains a clinical-stage company facing the substantial uncertainties associated with drug development, today's announcement gives investors a fresh research milestone to watch as the company advances its broader platform.

Today's News: Genprex to Present New TUSC2 Research in November

Genprex announced on October 28 that research conducted through its sponsored collaboration with Meharry Medical College will be featured at the GSA 2026 Annual Scientific Meeting, scheduled for November 4–7 in National Harbor, Maryland. The presentation will examine TUSC2 gene therapy in relation to cellular resilience and biological processes associated with aging.

The scheduled presentation is titled "TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program." It is listed for the conference's Late Breaking Poster Session I on November 4, from 6:00 to 7:15 p.m. Eastern Time. Genprex Chief Medical Officer Mark S. Berger, M.D., is identified as the presenter.

The announcement is notable because TUSC2 is already central to the company's oncology strategy. REQORSA, also known as quaratusugene ozeplasmid, is an investigational gene therapy designed to deliver the TUSC2 tumor-suppressor gene. The collaboration is examining the gene's wider biological activities, including mitochondrial metabolism, cellular stress responses and molecular processes associated with aging.

Genprex established the sponsored research collaboration with Meharry in 2024 and has continued to broaden its investigation into TUSC2 biology. The latest presentation offers another opportunity for the scientific community to examine findings generated through that work.

Importantly, the research should be viewed as an expansion of scientific understanding—not evidence that REQORSA treats aging or age-related diseases. Further investigation would be required to establish whether the findings support additional therapeutic applications.

For investors, the immediate takeaway is that Genprex continues to generate research milestones around a gene that underpins its lead oncology candidate, creating additional scientific visibility while its principal therapeutic programs progress.

October 21 Research Adds Another Layer to the TUSC2 Story

Today's announcement follows another important research update released October 21, when Genprex highlighted a peer-reviewed study published in Mechanisms of Ageing and Development. Researchers at Meharry Medical College investigated the role of TUSC2 in maintaining cellular function during brain aging.

The study examined an engineered mouse model in which TUSC2 was absent. Researchers associated TUSC2 loss with disruptions in mitochondrial function, protein quality control and pathways involved in communication between neurons. The effects differed between male and female mice, with more pronounced disruptions observed in males.

The researchers also examined existing human gene-expression datasets, finding that TUSC2 expression declined with age in 11 of 13 brain regions evaluated. Additional reductions were identified in Alzheimer's disease datasets, while comparisons revealed molecular similarities between the mouse findings and human brain-aging data.

Why does this matter to GNPX investors? TUSC2 is not simply a gene being studied in isolation; it is the foundation of the company's lead investigational oncology therapy. A deeper understanding of its biological functions could help researchers explore new scientific questions and refine their understanding of the company's platform.

However, the study was not a clinical trial of REQORSA for Alzheimer's disease, cognitive decline or aging. Any therapeutic implications outside oncology remain exploratory. The near-term investment case therefore continues to depend primarily on progress in Genprex's cancer and diabetes programs.

Roche Diagnostics Collaboration Targets More Personalized Lung Cancer Treatment

One of Genprex's most consequential recent strategic developments arrived on August 3, when the company announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies for non-small cell lung cancer (NSCLC).

The collaboration focuses on TROP2 and PTEN, two biomarkers that could help researchers identify patients more likely to respond to REQORSA. Earlier clinical findings presented at the 2026 American Society of Clinical Oncology meeting suggested that patients with higher TROP2 expression or lower PTEN expression experienced longer progression-free survival in the studied patient groups.

The Roche collaboration is designed to validate relevant biomarker testing methods, with Genprex anticipating completion around the end of 2026. Subject to the results, the company expects to evaluate incorporating the validated approach into its NSCLC clinical program.

This is an important development because identifying patients most likely to benefit from a treatment can be a valuable part of clinical development. Better patient selection could help researchers design more targeted studies and improve their understanding of treatment response.

For investors, the milestones to watch include validation results, potential incorporation of biomarker-based selection into clinical trials, and subsequent clinical data. These are prospective opportunities, not guarantees of improved outcomes or regulatory approval.

Diabetes Gene Therapy Advances Toward Manufacturing Scale-Up

Genprex is also developing a separate gene therapy program targeting diabetes, giving the company a second major therapeutic area beyond oncology.

On August 18, the company announced that it had selected a U.S.-based contract development and manufacturing organization to begin scaling up production of its adeno-associated virus (AAV)-based diabetes gene therapy. The manufacturing agreement is intended to support production under current Good Manufacturing Practice standards for investigational development and future clinical trials.

The candidate uses the Pdx1 and MafA genes, delivered to the pancreas using an AAV vector, with the goal of restoring insulin-producing beta-cell function.

Genprex has reported encouraging preclinical findings, including sustained blood-glucose improvements in Type 1 diabetes animal models and favorable measures involving insulin requirements, C-peptide and glucose tolerance in non-human primate studies. Related approaches have also shown encouraging findings in Type 2 diabetes models. These results remain preclinical and do not establish effectiveness in humans.

The manufacturing step is nevertheless meaningful: developing a potential therapy requires not only a scientific rationale but also a reproducible production process capable of supporting formal studies. Genprex's work on manufacturing and delivery approaches could help prepare the program for subsequent development milestones.

Additional Developments Investors Should Watch

Several other developments round out Genprex's current investment narrative:
  • Clinical biomarker research: Findings presented at ASCO in May 2026 added to the company's investigation of biomarkers associated with REQORSA treatment response.
  • Intellectual property: On June 22, Genprex announced a notice of allowance from the Canadian Intellectual Property Office for a patent claim involving REQORSA combined with PD-1 or PD-L1 antibodies for cancer treatment.
  • Upcoming scientific visibility: The November 4–7 GSA meeting provides the next specifically announced research presentation highlighted in the October 28 release.

Genprex also reported regaining Nasdaq's minimum-bid-price compliance on August 5. The associated panel requirements included maintaining a closing bid price of at least $1.00 through December 7, 2026, making continued listing compliance another important item to monitor.

$GNPX Outlook: Scientific Progress Meets Important Upcoming Milestones

Genprex enters the final months of 2026 with several developments that warrant attention: fresh TUSC2 research, a scheduled scientific presentation, biomarker validation work with Roche Diagnostics and manufacturing preparations for its diabetes program.

The company's opportunity rests on whether its scientific platform can translate into reproducible clinical benefits and, ultimately, viable treatments. The next meaningful checkpoints include the GSA presentation, further updates on the REQORSA clinical program, Roche-related validation progress and additional diabetes development announcements.

For more information on $GNPX visit: www.genprex.com      and https://compasslivemedia.com/gnpx/

Media Contact:
Company Name: Genprex, Inc.
Contact: Kalyn Dabbs
Email: [email protected]
Phone: (877) 774-GNPX (4679)
Country: United States
Website: www.genprex.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website

Contact
CorporateAds
***@gmail.com

Photos: (Click photo to enlarge)




Source: CorporateAds

Read Full Story - New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX) | More news from this source

Press release distribution by PRLog
MORE NEWS
Sangmidang seeks North American, European expansion through global partnerships
Oct 28, 2026
Sangmidang seeks North American, European expansion through global partnerships

Hur Jin-soo, vice chairman of Korean bakery giant Sangmidang Holdings, met Gellert Global Group (GGG) Chairman George Gellert and U.S. Ambassador to France Charles Kushner in Paris earlier this week to explore broader partnerships in overseas markets. Sangmidang said Wednesday that Hur discussed business developments and potential cooperation with Gellert and other GGG executives. Samlip, Sangmidang’s mass-market bakery subsidiary, could work with GGG to expand through U.S. supermarket and food service distribution networks and potentially enter Canada and Mexico, the Korean company said. U.S.-based GGG imports and distributes food products to retailers, food service distributors, restaurants, hotels, cruise operators and food manufacturers across North America. It sources more than 4,000 products from 60 countries and generates more than $1.7 billion in sales per year. The discussion first took place on Oct. 18 when Hur attended a reception for GGG’s partner firms at the U.S. ambassador’s residence in Paris. Hosted by Kushner, the event brought together about 130 representatives

Hanwha's KAI bid bodes well for another defense leap forward
Oct 28, 2026
Hanwha's KAI bid bodes well for another defense leap forward

Hanwha Group’s potential acquisition of Korea Aerospace Industries (KAI) could give the country’s aerospace and defense industry a much-needed boost in the global market, as privately owned defense firms have significantly outpaced their state-backed rival in sales growth. Yet transferring control of a strategically important company to a private conglomerate would also raise questions over national security, market concentration and the public investment underpinning its technological achievements. KAI has remained under state ownership since its establishment in 1999, with the state-run Export-Import Bank of Korea as its largest shareholder, holding a 26.41 percent stake. Hanwha is the second-largest shareholder, with a 15.89 percent stake. KAI’s relatively modest growth compared with private-sector defense counterparts highlights the potential benefits of a change in ownership. Lagging behind other private defense firms, KAI’s annual sales reached 3.69 trillion won ($2.79 billion) in 2025, inching down from 3.81 trillion won in 2023. Over the same period, LIG Defense & Aerospac

Debate grows over KAI privatization as Hanwha aims to expand stake
Oct 28, 2026
Debate grows over KAI privatization as Hanwha aims to expand stake

The privatization of Korea Aerospace Industries (KAI) could gain momentum as the state-run Export-Import Bank of Korea (Eximbank) commissions a 1.8 billion won ($1.36 million) consulting project and the Fair Trade Commission (FTC) highlights the benefits of stronger competition among major defense companies. Although Eximbank and KAI have expressed reservations about a change in ownership, KAI’s slower growth compared to its defense industry peers, despite a boom in arms exports, is fueling calls for privatization. Eximbank is KAI’s largest shareholder, with a 26.41 percent stake. According to Rep. Ahn Sang-hoon of the main opposition People Power Party and other sources, Eximbank recently selected AT Kearney as the preferred bidder for the consulting project and is proceeding with the subsequent steps. The project will examine ways to strengthen Korea’s aerospace industry and foster global anchor companies. Reports that the project was initiated at the government’s request have also sparked controversy. On Oct. 20, KAI CEO Kim Jong-chool said the company’s ownership structure

EMAT seeks to reduce China reliance on rare earth magnets with Pohang facility
Oct 28, 2026
EMAT seeks to reduce China reliance on rare earth magnets with Pohang facility

Evolution Metals & Technologies (EMAT), a Nasdaq-listed rare earth magnet producer, is making a big bet on Pohang, North Gyeongsang Province, by building a facility capable of producing 10,000 tons of sintered rare earth magnets annually for export to the U.S. and to other global customers seeking to reduce their reliance on China's dominant rare earth supply chain. The company plans to invest approximately 300 billion won ($224 million) in Pohang, including 223.8 billion won earmarked for building initial production capacity on a 118,000-square-meter site at the Blue Valley Industrial Complex in the city by 2027. EMAT and the Pohang city government signed a memorandum of understanding (MOU) on the investment project on Tuesday, with the city pledging administrative support for EMAT's plans. During an interview with The Korea Times, EMAT CEO Frank Moon stressed the need to distinguish between upstream and downstream operations. Citing China's dominance in the supply chain, he said geopolitical issues weigh heavily on the industry, and customers’ growing demand for alternatives to Chi

Regional airports to expand international flights by 11.6% for winter season
Oct 28, 2026
Regional airports to expand international flights by 11.6% for winter season

Korea Airports Corp., which operates 14 airports nationwide, said Wednesday that airlines will operate 10,208 scheduled flights a week during this winter season, which runs from Oct. 25 through March 27, 2027. International services will account for 3,206 weekly flights, up 11.6 percent, or 332 flights, from the summer schedule, while domestic services will total 7,002 flights a week. The expansion comes as the government seeks to attract 30 million foreign visitors ahead of schedule, with additional airport slots at Gimhae and Cheongju allowing more takeoffs and landings. Gimhae International Airport’s hourly capacity will increase from 27 to 30 flights, while Cheongju’s will rise from eight to 10, the airport operator said. Southeast Asian routes will increase 32.7 percent from the summer schedule to 600 flights a week, while services to China will rise 17.5 percent to 844 weekly flights. New China routes include Gimhae-Xiamen, Gimhae-Guangzhou, Cheongju-Xiamen and Jeju-Shijiazhuang. Gimhae will also introduce daily charter flights to Tokyo’s Haneda Airport starting in December and

Hana Financial opens digital vocational classroom for students with developmental disabilities
Oct 28, 2026
Hana Financial opens digital vocational classroom for students with developmental disabilities

Hana Financial Group has opened a digital classroom at a special education school in Seoul to help students with developmental disabilities explore career options and practice workplace skills, the group said Wednesday. The classroom at Miral School in Gangnam District is designed to give students hands-on experience in settings modeled on real workplaces, such as restaurants and cafes. The space is equipped with a range of digital learning tools, including a humanoid robot that can interact through voice conversations, virtual reality devices for vocational training, multimedia kiosks, interactive LED whiteboards and tablets for design practice. The classroom is the first step in Hana Financial’s wider program to aid students with developmental disabilities prepare for working life through digital learning and vocational training. The group plans to establish similar facilities at two more special education schools in Incheon and Daejeon by the first half of next year. Hana is also offering support for teachers and other school staff, with programs aimed at strengthening their profess

Hyundai Motor rises to No. 29 in Interbrand's global brand ranking
Oct 28, 2026
Hyundai Motor rises to No. 29 in Interbrand's global brand ranking

Hyundai Motor rose to 29th place in Interbrand’s Best Global Brands 2026 ranking, up two places from a year earlier, with its brand value reaching $25 billion, the automaker said Wednesday. The annual ranking by global brand consultancy Interbrand evaluates brands based on their financial performance, influence on consumers’ purchasing decisions and ability to build long-term loyalty. Hyundai also climbed to fourth among automotive brands from sixth in 2025, extending its streak of annual brand value growth to 17 consecutive years. Hyundai attributed the improvement to its strengthened vehicle lineup, investments in future growth areas such as physical artificial intelligence (AI) and software-defined vehicles (SDVs), and global marketing campaigns tied to major sporting events and cultural initiatives. “Seventeen consecutive years of brand value growth comes from customers who chose Hyundai and from the teams and dealer partners who earned that trust,” Hyundai Motor President and CEO Jose Munoz said. “Improving to fourth among automotive brands reflects both the strength of our

SK Broadband, LS Marine Solution team up to protect vital Asia cable link
Oct 28, 2026
SK Broadband, LS Marine Solution team up to protect vital Asia cable link

SK Broadband, the telecommunications unit of SK Group, is strengthening safeguards around a vital undersea cable linking Korea with Japan and Singapore, partnering with marine engineering specialist LS Marine Solution to speed up emergency repairs along vulnerable coastal stretches. The companies signed an agreement Tuesday to improve the reliability of the Southeast Asia-Japan Cable 2 (SJC2) submarine cable system, SK Broadband said Wednesday. Under the agreement, the companies will maintain emergency response vessels and specialized equipment while standardizing technical data and repair procedures in advance. The goal is to coordinate the entire recovery process, from dispatching crews to retrieving damaged cables, reconnecting lines and precisely reburying them on the seabed, reducing the time needed to restore service. The partnership will focus particularly on shallow coastal waters off Busan, where large vessels have difficulty operating and emergency repairs require specialized marine expertise and rapid response. SK Broadband will contribute cable analysis data and monitoring cap

SK On passes large-scale fire test, bolstering ESS safety credentials
Oct 28, 2026
SK On passes large-scale fire test, bolstering ESS safety credentials

SK On, the battery manufacturing unit of SK Group, passed a major fire safety test for its energy storage systems (ESS), clearing a key hurdle as the company seeks to expand in the global market for grid-scale energy storage. The company said Wednesday that its ESS products met evaluation criteria under UL 9540A, a North American standard used to assess how thermal runaway in batteries can spread heat and fire to surrounding equipment. The large-scale fire test recreates conditions resembling an actual energy storage system fire, examining whether flames or dangerous heat spread to neighboring battery containers. The requirements were tightened in March to establish clearer criteria for assessing fire propagation. During the test, battery cells inside adjacent containers did not experience thermal runaway caused by heat from the container where the fire originated, and temperatures inside the containers remained within the evaluation limits, SK On said. The company attributed the result to a system design that releases heat gradually over an extended period, limiting sudden increases in h

LG Uplus, Ecolab Korea team up to set AI data center cooling standards
Oct 28, 2026
LG Uplus, Ecolab Korea team up to set AI data center cooling standards

As artificial intelligence (AI) servers pack more computing power into less space, the heat they generate is becoming a critical challenge for data centers, prompting LG Uplus and Ecolab Korea to develop standards for liquid cooling systems. The companies signed a memorandum of understanding Tuesday at LG Uplus’ headquarters in Seoul's Yongsan District, to improve cooling system operations and establish procedures for managing coolant quality. The partnership combines LG Uplus’ expertise in building and operating AI data centers with Ecolab Korea’s water treatment and cooling fluid management technologies. The growing use of high-performance graphics processing units (GPUs) has increased heat output in data centers, driving interest in liquid cooling, which can remove heat more efficiently than conventional air cooling. But coolant that deteriorates or equipment that is poorly maintained can undermine cooling performance and lead to hardware failures, making consistent monitoring and operating standards essential. LG Uplus will provide a large-scale liquid cooling test environment b

Bithumb, Mirae Asset, Daishin join growing list of cyberattack victims
Oct 28, 2026
Bithumb, Mirae Asset, Daishin join growing list of cyberattack victims

Cryptocurrency exchange Bithumb, asset manager Mirae Asset Global Investments and Daishin Securities have become the latest victims of cyberattacks sweeping Korea’s financial sector, industry officials and financial authorities said Wednesday. Daishin Securities said in a press release earlier in the day that personal and credit information belonging to 38,490 customers had been leaked. The brokerage said it detected signs of unauthorized access by a hacker on Oct. 17 to a server linked to online securities account openings for discretionary investment services. Bithumb discovered Tuesday that personal information had been leaked following unauthorized access to its internal mobile groupware system. It is examining the scope of the breach, including whether customer information was compromised. A hacking incident was also reported at Mirae Asset Global Investments, prompting financial authorities to investigate the extent of the damage and the circumstances of the breach. The latest incidents came after Mirae Asset Life Insurance detected unusual activity in some of its systems Sunday

SK hynix pledges to return $75 bil. to shareholders
Oct 28, 2026
SK hynix pledges to return $75 bil. to shareholders

SK hynix on Wednesday announced a 100 trillion won ($75 billion) shareholder return plan for this year, in order to address the mismatch between its sluggish share price and record-breaking earnings performance. During its third-quarter earnings call, the company said it plans to return 100 trillion won to shareholders, including at least 30 trillion won in cash dividends and more than 60 trillion won through share buybacks and cancellations. “We believe our shares are undervalued, as their current price does not fully reflect the profits and cash flow the company is generating," the company said. "Under these circumstances, we believe repurchasing and canceling our shares is an effective way to increase value per share." "We plan to continue repurchasing shares every quarter within our annual buyback plan," it added. "The board will determine the size of quarterly repurchases after considering share prices, valuations and cash flow." The plan includes the recently completed 40 trillion won share buyback program, with the repurchased shares scheduled to be canceled soon. At a board meet

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

About Us

Always dynamic, always updated, The Witness Daily ensures minute-by-minute update to the most pressing issues, curated specifically to cater to critical newsreaders of our time.

Copyright © 2015 - 2026 Redshift Daily. All Rights Reserved.